Trump Imposes 200% Tariff on Generic Drugs, Threatening $9.7 Billion Indian Export Market

Trump unveiled a two‑stage tariff schedule for imported generic medicines, imposing a 0% duty beginning August 1 2026 and escalating to a 200% surcharge after two years, aiming to protect domestic producers and increase drug prices in the United States.

Indian Pharma Exports climbed 9% to $30.47 billion in the 2024‑25 fiscal year, the Commerce Secretary reported, while industry forecasts project a further 9‑11% expansion in 2026 as companies prioritize higher‑quality standards.

India’s Generic Drug Segment, valued at roughly $9.7 billion in U.S. sales, could lose market share if the 200% tariff forces American buyers to switch to alternative suppliers or absorb steep price hikes, raising concerns for exporters.

Industry Analysts argue that Indian manufacturers may mitigate the impact by enhancing product quality, diversifying into non‑U.S. markets, and leveraging cost advantages, and some reports suggest the tariff may ultimately have limited effect on total export volumes.